Bone Historical Cash Flow
| BBLG Stock | USD 0.89 0.05 5.32% |
Analysis of Bone Biologics cash flow over time is an excellent tool to project Bone Biologics Corp future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 1.7 M or Other Cashflows From Financing Activities of 8 M as it is a great indicator of Bone Biologics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Bone Biologics Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Bone Biologics Corp is a good buy for the upcoming year.
Bone |
About Bone Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Bone balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Bone's non-liquid assets can be easily converted into cash.
Bone Biologics Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Net Borrowings
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.Most accounts from Bone Biologics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Bone Biologics Corp current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At this time, Bone Biologics' Net Borrowings is most likely to decrease significantly in the upcoming years. The Bone Biologics' current Change To Operating Activities is estimated to increase to about 54.3 K, while Free Cash Flow is forecasted to increase to (3.9 M).
Bone Biologics cash flow statement Correlations
Click cells to compare fundamentals
Bone Biologics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bone Biologics cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (24.1K) | 6.7M | 862.9K | (4.5M) | 298.6K | 242.8K | |
| Free Cash Flow | (426.9K) | (1.2M) | (3.6M) | (9.6M) | (4.1M) | (3.9M) | |
| Begin Period Cash Flow | 24.1K | 2.5K | 6.7M | 7.5M | 3.0M | 1.7M | |
| Other Cashflows From Financing Activities | 805.6K | 1.1M | 4.4K | 5.0K | 7.6M | 8.0M | |
| Other Non Cash Items | 938.1K | 495.6K | (2.2M) | (892.7K) | (201.3K) | (191.3K) | |
| Total Cash From Operating Activities | (426.9K) | (1.2M) | (3.6M) | (9.6M) | (4.1M) | (3.9M) | |
| Net Income | (1.8M) | (1.6M) | (1.5M) | (8.9M) | (4.1M) | (4.3M) | |
| Total Cash From Financing Activities | 402.8K | 7.9M | 4.4M | 5.0M | 4.4M | 3.0M | |
| End Period Cash Flow | 2.5K | 6.7M | 7.5M | 3.0M | 3.3M | 2.0M | |
| Change In Working Capital | 399.7K | (320.5K) | (168.4K) | 132.9K | 152.9K | 160.5K | |
| Stock Based Compensation | 60K | 207.0K | 266.6K | 152.6K | 188.8K | 179.4K | |
| Change To Operating Activities | 212.4K | 208.6K | 66.7K | 45K | 51.8K | 54.3K | |
| Change To Netincome | (182.1K) | 29.8K | 60K | 702.6K | 632.3K | 600.7K | |
| Change To Liabilities | (66.9K) | (64.8K) | 333K | (365.5K) | (328.9K) | (312.5K) |
Currently Active Assets on Macroaxis
When determining whether Bone Biologics Corp is a strong investment it is important to analyze Bone Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bone Biologics' future performance. For an informed investment choice regarding Bone Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.